plasma tacrolimus concentrations are vulnerable to hemolysis (Størset et al
, 2014)
Table 2
Several methods including immunoassays have been used for monitoring tacrolimus levels
This causes red blood cells to break down earlier than normal, a process called hemolysis
Currently CAD is defined as a chronic, clonal lymphoproliferative disorder, while the presence of cold agglutinins underlying other diseases is Tacrolimus is one of the major treatment options for systemic lupus erythematosus (SLE) and is considered to be a pregnancy-compatible medication
Tacrolimus was administered at an initial dose of 0
Seven out of eight patients who received tacrolimus for rejection therapy improved
Pure red cell aplasia (PRCA) is a less common cause of anemia, and the etiologies range from congenital diseases to acquired causes such as viral infections, drugs, EPO therapy, malignancies, connective tissue disorders and idiopathic [ 2 ]
Large interindividual variability in the pharmacokinetics ( 2) and the nephrotoxicity of tacrolimus ( 3) necessitates routine monitoring of this agent in transplant patients
Repeated peripheral smears showed no evidence of hemolysis A total of 36 patients were screened for inclusion, of which 8 were excluded due to acute renal failure and/or hemolysis
pinpoint red spots on the skin
[1,2] This is the first report of tacrolimus induced hyperkalemia in OHT recipients
Tacrolimus-related posttransplant lymphoproliferative disorder presenting as autoimmune hemolytic anemia
β-HCG was negative, and her ADAMTS13 activity level was 76% (normal >60%)
Both cases resolved after drug cessation; the first patient received also therapeutic The calcineurin inhibitor tacrolimus is an effective immunosuppressant and is extensively used in solid organ transplantation
The incidence of drug-induced immune thrombocytopenia and neutropenia is quite well documented (10 to 18 and 2 to 15 cases per million, respectively), 1, - 3 but there are no good data for DIIHA
Although the number of patients treated with tacrolimus was limited, our results did not show a difference in response with use of tacrolimus compared with CsA
The symptoms and signs of thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome Symptoms and Signs Hemolytic-uremic syndrome (HUS) is an acute, fulminant disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, and acute kidney injury
We retrospectively examined our data to identify the tacrolimus trough concentration that combined efficacy with minimal adverse effects